Funding News Edition: February 15, 2023 See more articles in this edition
The Office of Research on Women’s Health (ORWH) announced Notice of Special Interest (NOSI): Research on Gender Measurement (Admin Supp, Clinical Trial Optional) to support research testing gender terminology (e.g., woman, man, nonbinary) for measuring current gender identity as part of the two-step method of data collection (sex assigned at birth and current gender identity).
Through this NOSI, participating NIH Institutes and Centers register their interest in providing administrative supplements to grantees testing gender terminology within ongoing data collection.
NIAID-Specific Areas of Research Interest
NIAID’s mission is to support basic and translational research that improves the understanding, diagnosis, prevention, and treatment of infectious and immune-mediated diseases, as well as advanced immunologic and transplantation strategies. Because these conditions impact the health of sexual minority and majority populations, NIAID endorses adopting a meaningful sexual orientation and gender identity (SOGI) measurement in research, clinical care, and administrative settings.
NIAID is also interested in mission-relevant research that evaluates expanded gender identity options for data collection such as:
- Cisgender man
- Cisgender woman
- Two-spirit (for indigenous populations)
Review the NOSI for additional details.
To be eligible for an administrative supplement, you must hold an active grant or cooperative agreement from NIH. This NOSI supports supplements for all activity codes. NIAID encourages applicants to collaborate with their organizations to develop applications for support.
Note: NIAID considers Specific Aims added to the parent grant through the SARS-CoV-2/COVID-19 Competitive Revisions process to be part of the parent application and thus eligible to apply for a supplement under this NOSI.
Investigators must fulfill all of the following requirements, otherwise NIAID will deem their applications to be nonresponsive to this NOSI.
- The parent peer-reviewed NIH funded grant must have at least 16 months of active grant support remaining from the due date. No-cost extension is not an eligibility criterion. NIAID may make an exception for proposals studying SARS-CoV-2 or COVID-19.
- The proposed research must address Objective 2.2 of the 2019-2023 Advancing Science for the Health of Women: The Trans-NIH Strategic Plan for Women’s Health Research, which is to develop and adapt reliable and valid measures related to women’s health.
Non-domestic entities (non-U.S., foreign institutions) and non-domestic components of U.S. organizations are not eligible to apply. However, Foreign Components are allowed.
ORWH intends to commit up to $450,000 for this program and the application budget should not exceed $100,000 in direct costs and is limited to 1 year only.
NIH program staff will conduct administrative reviews of the application submissions; the most meritorious applications will receive funding consideration pending availability of funds. The proposed project period cannot exceed that of the parent award.
Application and Submission Information
Continuous submission is not permitted and NIAID will not accept late applications.
Applicants must apply to this initiative using the following funding opportunity announcement (FOA): Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp, Clinical Trial Optional). Follow all instructions in the SF 424 (R&R) Application Guide and the FOA.
For funding consideration, applicants must include “NOT-OD-23-046" in the Agency Routing Identifier field (box 4B) of the SF 424 R&R form. NIAID will consider applications that lack this information in box 4B to be nonresponsive.
Act quickly! Applications are due on February 28, 2023, by 5 p.m. local time of the applicant organization.
Send any inquiries about this initiative to ORWH’s Dr. Elizabeth Barr at email@example.com or 301-402-7895.